Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Multiple Sclerosis

  Free Subscription


Articles published in Acta Neurol Scand

Retrieve available abstracts of 100 articles:
HTML format



Single Articles


    March 2021
  1. KAVALIUNAS A, Danylaite Karrenbauer V, Hillert J
    Socioeconomic consequences of multiple sclerosis-A systematic literature review.
    Acta Neurol Scand. 2021 Mar 22. doi: 10.1111/ane.13411.
    PubMed     Abstract available


    February 2021
  2. OLSSON A, Gustavsen S, Gisselo Lauridsen K, Chenoufi Hasselbalch I, et al
    Neutrophil-to-lymphocyte ratio and CRP as biomarkers in multiple sclerosis: A systematic review.
    Acta Neurol Scand. 2021 Feb 16. doi: 10.1111/ane.13401.
    PubMed     Abstract available


    December 2020
  3. TEKEOGLU A, Yeldan I, Ozdincler AR, Saip S, et al
    The efficiency of mirror therapy on drop foot in Multiple Sclerosis Patients.
    Acta Neurol Scand. 2020 Dec 3. doi: 10.1111/ane.13385.
    PubMed     Abstract available


    November 2020
  4. BORGSTROM M, Tisell A, Link H, Wilhelm E, et al
    Retinal thinning and brain atrophy in early MS and CIS.
    Acta Neurol Scand. 2020;142:418-427.
    PubMed     Abstract available


    September 2020
  5. CHESHMAVAR M, Mirmosayyeb O, Badihian N, Badihian S, et al
    Rituximab and glatiramer-acetate in secondary-progressive multiple sclerosis: A randomized-clinical trial.
    Acta Neurol Scand. 2020 Sep 8. doi: 10.1111/ane.13344.
    PubMed     Abstract available


    August 2020
  6. JONS D, Zetterberg H, Malmestrom C, Bergstrom T, et al
    Intrathecal immunoreactivity in people with or without previous infectious mononucleosis.
    Acta Neurol Scand. 2020;142:161-168.
    PubMed     Abstract available


    July 2020
  7. WANDELL P, Fredrikson S, Carlsson AC, Li X, et al
    Multiple sclerosis among first- and second-generation immigrant groups in Sweden.
    Acta Neurol Scand. 2020 Jul 10. doi: 10.1111/ane.13314.
    PubMed     Abstract available


  8. VECCHIO D, Varrasi C, Virgilio E, Spagarino A, et al
    Cannabinoids in multiple sclerosis: A neurophysiological analysis.
    Acta Neurol Scand. 2020 Jul 6. doi: 10.1111/ane.13313.
    PubMed     Abstract available


    June 2020
  9. LAHDENPERA S, Soilu-Hanninen M, Kuusisto HM, Atula S, et al
    Medication adherence/persistence among patients with active multiple sclerosis in Finland.
    Acta Neurol Scand. 2020 Jun 19. doi: 10.1111/ane.13301.
    PubMed     Abstract available


  10. PIRTTISALO AL, Soilu-Hanninen M, Sumelahti ML, Krokki O, et al
    Changes in multiple sclerosis epidemiology in Finland over five decades.
    Acta Neurol Scand. 2020 Jun 4. doi: 10.1111/ane.13295.
    PubMed     Abstract available


    May 2020
  11. MAMOEI S, Hvid LG, Boye Jensen H, Zijdewind I, et al
    Neurophysiological impairments in multiple sclerosis - central and peripheral motor pathways.
    Acta Neurol Scand. 2020 May 31. doi: 10.1111/ane.13289.
    PubMed     Abstract available


  12. ZANONI M, Orlandi E, Rossetti G, Turatti M, et al
    Up-regulated serum miR-128-3p in progressive and relapse-free multiple sclerosis patients.
    Acta Neurol Scand. 2020 May 20. doi: 10.1111/ane.13288.
    PubMed     Abstract available


  13. COSTA ARPIN E, Naveiro Soneira J, Lema Bouzas M, Quintela AG, et al
    Epidemiology of multiple sclerosis IN Santiago de Compostela (Spain).
    Acta Neurol Scand. 2020 May 11. doi: 10.1111/ane.13265.
    PubMed     Abstract available


    March 2020
  14. REYES S, Suarez S, Allen-Philbey K, Thomson A, et al
    The impact of social capital on patients with multiple sclerosis.
    Acta Neurol Scand. 2020 Mar 18. doi: 10.1111/ane.13244.
    PubMed     Abstract available


  15. LAAKSO SM, Hekali O, Kurdo G, Martola J, et al
    Trigeminal neuralgia in multiple sclerosis: prevalence and association with demyelination.
    Acta Neurol Scand. 2020 Mar 18. doi: 10.1111/ane.13243.
    PubMed     Abstract available


  16. WILSKI M, Kocur P, Brola W, Tasiemski T, et al
    Psychological factors associated with self-management in multiple sclerosis.
    Acta Neurol Scand. 2020 Mar 2. doi: 10.1111/ane.13236.
    PubMed     Abstract available


  17. ZARGHAMI A, Nourmohammadi ST, Hojjati SMM
    Urbanization theory and socioeconomic changeover of multiple sclerosis in Iran.
    Acta Neurol Scand. 2020;141:256.
    PubMed    


    February 2020
  18. RASMAN A
    Air pollution, a risk factor for multiple sclerosis?
    Acta Neurol Scand. 2020 Feb 25. doi: 10.1111/ane.13235.
    PubMed     Abstract available


    January 2020
  19. HELLGREN J, Risedal A, Kallen K
    Rituximab in multiple sclerosis at general hospital level.
    Acta Neurol Scand. 2020 Jan 28. doi: 10.1111/ane.13225.
    PubMed     Abstract available


  20. TURK BORU U, Boluk C, Tasdemir M, Gezer T, et al
    Air pollution, a possible risk factor for multiple sclerosis.
    Acta Neurol Scand. 2020 Jan 18. doi: 10.1111/ane.13223.
    PubMed     Abstract available


    December 2019
  21. MURTONEN A, Sumelahti ML
    Multiple sclerosis prevalence in 2000 and 2010 in Western Finland.
    Acta Neurol Scand. 2019 Dec 14. doi: 10.1111/ane.13203.
    PubMed     Abstract available


    November 2019
  22. WALLIS O, Bol Y, Kohler S, van Heugten C, et al
    Anxiety in multiple sclerosis is related to depressive symptoms and cognitive complaints.
    Acta Neurol Scand. 2019 Nov 6. doi: 10.1111/ane.13191.
    PubMed     Abstract available


  23. SCOTT TF, Diehl D, Elmalik W, Gettings EJ, et al
    Multiple sclerosis relapses contribute to long-term disability.
    Acta Neurol Scand. 2019;140:336-341.
    PubMed     Abstract available


    October 2019
  24. SMOLDERS J, Mimpen M, Oechtering J, Damoiseaux J, et al
    Vitamin D3 supplementation and neurofilament light chain in multiple sclerosis.
    Acta Neurol Scand. 2019 Oct 28. doi: 10.1111/ane.13185.
    PubMed     Abstract available


  25. ZETTERBERG H
    Plasma neurofilament light in progressive multiple sclerosis.
    Acta Neurol Scand. 2019 Oct 16. doi: 10.1111/ane.13184.
    PubMed     Abstract available


  26. CASTREN E, Heinonen T, Makinen K, Hamalainen P, et al
    The rate of neuropsychological assessments in multiple sclerosis has increased - A retrospective study in a Finnish central hospital.
    Acta Neurol Scand. 2019 Oct 4. doi: 10.1111/ane.13175.
    PubMed     Abstract available


    July 2019
  27. FERRARO D, Guicciardi C, De Biasi S, Pinti M, et al
    Plasma Neurofilaments correlate with Disability in Progressive Multiple Sclerosis patients.
    Acta Neurol Scand. 2019 Jul 27. doi: 10.1111/ane.13152.
    PubMed     Abstract available


  28. TOLF A, Fagius J, Carlson K, Akerfeldt T, et al
    Sustained remission in multiple sclerosis after hematopoietic stem cell transplantation.
    Acta Neurol Scand. 2019 Jul 12. doi: 10.1111/ane.13147.
    PubMed     Abstract available


  29. PAKDEL M, Hedstrom A, Bidkhori M, Hadei M, et al
    Do socio-economic factors affect prevalence of multiple sclerosis in Iran?
    Acta Neurol Scand. 2019 Jul 10. doi: 10.1111/ane.13148.
    PubMed     Abstract available


  30. LAAKSO SM, Viitala M, Kuusisto H, Sarasoja T, et al
    Multiple sclerosis in Finland 2018- data from the national register.
    Acta Neurol Scand. 2019 Jul 4. doi: 10.1111/ane.13145.
    PubMed     Abstract available


  31. GUGER M, Enzinger C, Leutmezer F, Kraus J, et al
    Real-life use of oral disease-modifying treatments in Austria.
    Acta Neurol Scand. 2019;140:32-39.
    PubMed     Abstract available


    May 2019
  32. GASCOYNE CR, Simpson S Jr, Chen J, van der Mei I, et al
    Modifiable factors associated with depression and anxiety in multiple sclerosis.
    Acta Neurol Scand. 2019 May 23. doi: 10.1111/ane.13132.
    PubMed     Abstract available


  33. DE FLON P, Laurell K, Sundstrom P, Blennow K, et al
    Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial.
    Acta Neurol Scand. 2019;139:462-468.
    PubMed     Abstract available


  34. AXELSSON M, Dubuisson N, Novakova L, Malmestrom C, et al
    Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies.
    Acta Neurol Scand. 2019;139:422-427.
    PubMed     Abstract available


    March 2019
  35. CORTES-MARTINEZ A, Matias-Guiu JA, Pytel V, Montero P, et al
    What is the meaning of PASAT rejection in Multiple Sclerosis?
    Acta Neurol Scand. 2019 Mar 25. doi: 10.1111/ane.13090.
    PubMed     Abstract available


    February 2019
  36. ENGELS K, Schiffmann I, Weierstall R, Rahn AC, et al
    Emotions towards magnetic resonance imaging in people with multiple sclerosis.
    Acta Neurol Scand. 2019 Feb 25. doi: 10.1111/ane.13082.
    PubMed     Abstract available


  37. DE BERNARDO M, Vitiello L, Rosa N
    Optic nerve ultrasound measurement in multiple sclerosis.
    Acta Neurol Scand. 2019 Feb 5. doi: 10.1111/ane.13072.
    PubMed     Abstract available


  38. CANDELIERE MERLICCO A, Gabaldon Torres L, Villaverde Gonzalez R, Fernandez Romero I, et al
    Response to: Comment on "Transorbital ultrasonography for measuring optic nerve atrophy in multiple sclerosis".
    Acta Neurol Scand. 2019 Feb 5. doi: 10.1111/ane.13076.
    PubMed     Abstract available


  39. SANDROFF BM, Baird JF, Silveira SL, Motl RW, et al
    Response heterogeneity in fitness, mobility and cognition with exercise-training in MS.
    Acta Neurol Scand. 2019;139:183-191.
    PubMed     Abstract available


    January 2019
  40. RAHN AC, Kopke S, Stellmann JP, Schiffmann I, et al
    Magnetic resonance imaging as a prognostic disability marker in clinically isolated syndrome: A systematic review.
    Acta Neurol Scand. 2019;139:18-32.
    PubMed     Abstract available


    November 2018
  41. PIRTTISALO AL, Soilu-Hanninen M, Sipila JOT
    Multiple sclerosis epidemiology in Finland: regional differences and high incidence.
    Acta Neurol Scand. 2018 Nov 27. doi: 10.1111/ane.13057.
    PubMed     Abstract available


  42. DAL-BIANCO A, Wenhoda F, Rommer PS, Weber M, et al
    Do Elevated Autoantibodies in Patients With Multiple Sclerosis Matter ?
    Acta Neurol Scand. 2018 Nov 17. doi: 10.1111/ane.13054.
    PubMed     Abstract available


  43. MELBYE P, Olsson A, Hansen TH, Sondergaard HB, et al
    Short-Chain Fatty Acids and Gut Microbiota in Multiple Sclerosis.
    Acta Neurol Scand. 2018 Nov 14. doi: 10.1111/ane.13045.
    PubMed     Abstract available


  44. STEENHOF M, Nielsen NM, Stenager E, Kyvik K, et al
    Distribution of disease courses in familial versus sporadic multiple sclerosis.
    Acta Neurol Scand. 2018 Nov 9. doi: 10.1111/ane.13044.
    PubMed     Abstract available


    October 2018
  45. HOLMOY T, Rosjo E, Zetterberg H, Blennow K, et al
    Vitamin D supplementation and neurofilament light chain in multiple sclerosis.
    Acta Neurol Scand. 2018 Oct 13. doi: 10.1111/ane.13037.
    PubMed     Abstract available


  46. BAYART JL, Muls N, van Pesch V
    Free Kappa light chains in neuroinflammatory disorders: Complement rather than substitute?
    Acta Neurol Scand. 2018;138:352-358.
    PubMed     Abstract available


    August 2018
  47. HAGHIGHI S, Forsmark S, Carlsson A, Nilsson MKL, et al
    Open study with (-)-OSU6162 in multiple sclerosis-related fatigue.
    Acta Neurol Scand. 2018 Aug 22. doi: 10.1111/ane.13007.
    PubMed     Abstract available


  48. BAUMGARTNER A, Frings L, Schiller F, Stich O, et al
    Regional neuronal activity in patients with relapsing remitting multiple sclerosis.
    Acta Neurol Scand. 2018 Aug 8. doi: 10.1111/ane.13012.
    PubMed     Abstract available


    July 2018
  49. MURLEY C, Yang F, Gyllensten H, Alexanderson K, et al
    Disposable income trajectories of working-aged individuals with diagnosed multiple sclerosis.
    Acta Neurol Scand. 2018 Jul 24. doi: 10.1111/ane.13001.
    PubMed     Abstract available


  50. ROMEO MAL, Martinelli V, Dalla Costa G, Colombo B, et al
    Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response.
    Acta Neurol Scand. 2018 Jul 22. doi: 10.1111/ane.12999.
    PubMed     Abstract available


  51. GAVRILOV YV, Shkilnyuk GG, Valko PO, Stolyarov ID, et al
    Validation of the Russian version of the Fatigue Impact Scale and Fatigue Severity Scale in multiple sclerosis patients.
    Acta Neurol Scand. 2018 Jul 9. doi: 10.1111/ane.12993.
    PubMed     Abstract available


  52. CANDELIERE MERLICCO A, Gabaldon Torres L, Villaverde Gonzalez R, Fernandez Romero I, et al
    Transorbital ultrasonography for measuring optic nerve atrophy in multiple sclerosis.
    Acta Neurol Scand. 2018 Jul 2. doi: 10.1111/ane.12976.
    PubMed     Abstract available


    June 2018
  53. DALE GH, Svendsen KB, Gjelstrup MC, Christensen T, et al
    Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region.
    Acta Neurol Scand. 2018;137:582-588.
    PubMed     Abstract available


    May 2018
  54. BERNTSSON SG, Kristoffersson A, Bostrom I, Feresiadou A, et al
    Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?
    Acta Neurol Scand. 2018 May 24. doi: 10.1111/ane.12963.
    PubMed     Abstract available


  55. SEBASTIAO E, Motl RW
    Body mass index and cardiorespiratory fitness in persons with multiple sclerosis.
    Acta Neurol Scand. 2018 May 11. doi: 10.1111/ane.12959.
    PubMed     Abstract available


  56. ABDOLLAHPOUR I, Nedjat S, Mansournia MA, Eckert S, et al
    Infectious exposure, antibiotic use, and multiple sclerosis: A population-based incident case-control study.
    Acta Neurol Scand. 2018 May 9. doi: 10.1111/ane.12958.
    PubMed     Abstract available


    March 2018
  57. HEYDARPOUR P, Manouchehrinia A, Beiki O, Mousavi SE, et al
    Smoking and worsening disability in multiple sclerosis: A meta-analysis.
    Acta Neurol Scand. 2018 Mar 15. doi: 10.1111/ane.12916.
    PubMed     Abstract available


  58. VISTBAKKA J, Sumelahti ML, Lehtimaki T, Elovaara I, et al
    Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients.
    Acta Neurol Scand. 2018 Mar 12. doi: 10.1111/ane.12921.
    PubMed     Abstract available


  59. RAHMANZADEH R, Weber MS, Bruck W, Navardi S, et al
    B cells in multiple sclerosis therapy-A comprehensive review.
    Acta Neurol Scand. 2018 Mar 7. doi: 10.1111/ane.12915.
    PubMed     Abstract available


    February 2018
  60. MANI A, Chohedri E, Ravanfar P, Mowla A, et al
    Efficacy of group cognitive rehabilitation therapy in multiple sclerosis.
    Acta Neurol Scand. 2018 Feb 7. doi: 10.1111/ane.12904.
    PubMed     Abstract available


  61. GUGER M, Enzinger C, Leutmezer F, Kraus J, et al
    Real-life clinical use of natalizumab and fingolimod in Austria.
    Acta Neurol Scand. 2018;137:181-187.
    PubMed     Abstract available


  62. NICKEL S, von dem Knesebeck O, Kofahl C
    Self-assessments and determinants of HRQoL in a German MS population.
    Acta Neurol Scand. 2018;137:174-180.
    PubMed     Abstract available


    January 2018
  63. MESCHERIAKOVA JY, Hintzen RQ
    No excess of autoimmune diseases in multiple sclerosis families from the Netherlands.
    Acta Neurol Scand. 2018 Jan 7. doi: 10.1111/ane.12896.
    PubMed     Abstract available


  64. RORSMAN I, Petersen C, Nilsson PC
    Cognitive functioning following one-year natalizumab treatment: A non-randomized clinical trial.
    Acta Neurol Scand. 2018;137:117-124.
    PubMed     Abstract available


    December 2017
  65. OLSSON A, Oturai AB, Sondergaard HB, Sellebjerg F, et al
    Bone microarchitecture and bone mineral density in multiple sclerosis.
    Acta Neurol Scand. 2017 Dec 21. doi: 10.1111/ane.12884.
    PubMed     Abstract available


  66. ZECCA C, Antozzi CG, Torri Clerici V, Ferrazzini M, et al
    Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.
    Acta Neurol Scand. 2017 Dec 3. doi: 10.1111/ane.12882.
    PubMed     Abstract available


  67. HEESEN C, Haase R, Melzig S, Poettgen J, et al
    Perceptions on the value of bodily functions in multiple sclerosis.
    Acta Neurol Scand. 2017 Dec 3. doi: 10.1111/ane.12881.
    PubMed     Abstract available


    November 2017
  68. ZETTERBERG H
    Fluid biomarkers for microglial activation and axonal injury in multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:15-17.
    PubMed     Abstract available


  69. LYCKE J
    Trials of antivirals in the treatment of multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:45-48.
    PubMed     Abstract available


  70. CELIUS EG
    Infections in patients with multiple sclerosis: Implications for disease-modifying therapy.
    Acta Neurol Scand. 2017;136 Suppl 201:34-36.
    PubMed     Abstract available


  71. WEKERLE H
    Nature, nurture, and microbes: The development of multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:22-25.
    PubMed     Abstract available


  72. FREDERIKSEN JL, Topsoe Mailand M
    Vaccines and multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:49-51.
    PubMed     Abstract available


  73. WENDEL-HAGA M, Celius EG
    Is the hygiene hypothesis relevant for the risk of multiple sclerosis?
    Acta Neurol Scand. 2017;136 Suppl 201:26-30.
    PubMed     Abstract available


    August 2017
  74. WALLIN MT, Culpepper WJ, Maloni H, Kurtzke JF, et al
    The Gulf War era multiple sclerosis cohort: 3. Early clinical features.
    Acta Neurol Scand. 2017 Aug 22. doi: 10.1111/ane.12810.
    PubMed     Abstract available


    July 2017
  75. ANDERSEN O, Hildeman A, Longfils M, Tedeholm H, et al
    Diffusion tensor imaging in multiple sclerosis at different final outcomes.
    Acta Neurol Scand. 2017 Jul 25. doi: 10.1111/ane.12797.
    PubMed     Abstract available


  76. CAMBRON M, Hadhoum N, Duhin E, Lacour A, et al
    JCV serology in time: 3 years of follow-up.
    Acta Neurol Scand. 2017;136:54-58.
    PubMed     Abstract available


    May 2017
  77. MENTIS AA, Dardiotis E, Grigoriadis N, Petinaki E, et al
    Viruses and endogenous retroviruses in multiple sclerosis: From correlation to causation.
    Acta Neurol Scand. 2017 May 23. doi: 10.1111/ane.12775.
    PubMed     Abstract available


    April 2017
  78. MARTINELLI V, Dalla Costa G, Messina MJ, Di Maggio G, et al
    Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes.
    Acta Neurol Scand. 2017 Apr 9. doi: 10.1111/ane.12761.
    PubMed     Abstract available


    March 2017
  79. ELKJAER ML, Molnar T, Illes Z
    Teriflunomide for multiple sclerosis in real-world setting.
    Acta Neurol Scand. 2017 Mar 20. doi: 10.1111/ane.12755.
    PubMed     Abstract available


  80. SCHNEIDER R, Bellenberg B, Kleiter I, Gold R, et al
    Cervical cord and ventricle affection in neuromyelitis optica.
    Acta Neurol Scand. 2017;135:324-331.
    PubMed     Abstract available


    February 2017
  81. ENSARI I, Pilutti LA, Motl RW
    Depressive symptomology in multiple sclerosis: Disability, cardiorespiratory fitness and heart rate variability.
    Acta Neurol Scand. 2017 Feb 26. doi: 10.1111/ane.12748.
    PubMed     Abstract available


    January 2017
  82. LUNDELL H, Svolgaard O, Dogonowski AM, Romme Christensen J, et al
    Spinal cord atrophy in anterior-posterior direction reflects impairment in multiple sclerosis.
    Acta Neurol Scand. 2017 Jan 10. doi: 10.1111/ane.12729.
    PubMed     Abstract available


  83. VOLDSGAARD A, Koch-Henriksen N, Magyari M, Sellebjerg F, et al
    Early safety and efficacy of fingolimod treatment in Denmark.
    Acta Neurol Scand. 2017;135:129-133.
    PubMed     Abstract available


    December 2016
  84. KARAMYAN A, Brandtner H, Grinzinger S, Chroust V, et al
    Causes of death in critically ill multiple sclerosis patients.
    Acta Neurol Scand. 2016 Dec 23. doi: 10.1111/ane.12724.
    PubMed     Abstract available


  85. TANASESCU R, Midgley A, Robins RA, Constantinescu CS, et al
    Decreased interferon-beta induced STAT-4 activation in immune cells and clinical outcome in multiple sclerosis.
    Acta Neurol Scand. 2016 Dec 5. doi: 10.1111/ane.12715.
    PubMed     Abstract available


  86. D'HOOGHE MB, Haentjens P, Van Remoortel A, De Keyser J, et al
    Self-reported levels of education and disability progression in multiple sclerosis.
    Acta Neurol Scand. 2016;134:414-419.
    PubMed     Abstract available


    November 2016
  87. PEARSON JF, Alla S, Clarke G, Mason DF, et al
    Multiple Sclerosis impact on employment and income in New Zealand.
    Acta Neurol Scand. 2016 Nov 28. doi: 10.1111/ane.12714.
    PubMed     Abstract available


  88. SOELBERG SORENSEN P
    Safety concerns and risk management of multiple sclerosis therapies.
    Acta Neurol Scand. 2016 Nov 27. doi: 10.1111/ane.12712.
    PubMed     Abstract available


    October 2016
  89. ZETTL UK, Schreiber H, Bauer-Steinhusen U, Glaser T, et al
    Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis.
    Acta Neurol Scand. 2016 Oct 30. doi: 10.1111/ane.12705.
    PubMed     Abstract available


  90. GOUVEIA A, Dias SP, Santos T, Rocha H, et al
    Cognitive impairment and magnetic resonance imaging correlates in primary progressive multiple sclerosis.
    Acta Neurol Scand. 2016 Oct 24. doi: 10.1111/ane.12702.
    PubMed     Abstract available


    September 2016
  91. PUZ P, Lasek-Bal A, Radecka P
    Transcranial sonography of subcortical structures in patients with multiple sclerosis.
    Acta Neurol Scand. 2016 Sep 18. doi: 10.1111/ane.12689.
    PubMed     Abstract available


  92. ROMMER PS, Suhnel A, Konig N, Zettl UK, et al
    Coping with multiple sclerosis-the role of social support.
    Acta Neurol Scand. 2016 Sep 12. doi: 10.1111/ane.12673.
    PubMed     Abstract available


  93. MUCKSCHEL M, Beste C, Ziemssen T
    Immunomodulatory treatments and cognition in MS.
    Acta Neurol Scand. 2016;134 Suppl 200:55-9.
    PubMed     Abstract available


  94. BERGER T
    Immunological processes related to cognitive impairment in MS.
    Acta Neurol Scand. 2016;134 Suppl 200:34-8.
    PubMed     Abstract available


  95. PAUL F
    Pathology and MRI: exploring cognitive impairment in MS.
    Acta Neurol Scand. 2016;134 Suppl 200:24-33.
    PubMed     Abstract available


  96. PORTACCIO E
    Differential diagnosis, discerning depression from cognition.
    Acta Neurol Scand. 2016;134 Suppl 200:14-8.
    PubMed     Abstract available


  97. HAMALAINEN P, Rosti-Otajarvi E
    Cognitive impairment in MS: rehabilitation approaches.
    Acta Neurol Scand. 2016;134 Suppl 200:8-13.
    PubMed     Abstract available


  98. VAN ETTINGER-VEENSTRA H
    Cumulative evidence for MS as a neural network disconnection syndrome consistent with cognitive impairment mechanisms and the confounding role of fatigue and depression-outlook from the Fourth Nordic MS symposium.
    Acta Neurol Scand. 2016;134 Suppl 200:4-7.
    PubMed     Abstract available


    May 2016
  99. KOLASA M, Hagman S, Verkkoniemi-Ahola A, Airas L, et al
    Anti-JC virus seroprevalence in a Finnish MS cohort.
    Acta Neurol Scand. 2016;133:391-7.
    PubMed     Abstract available


    April 2016
  100. HOLMOY T, Esbensen QY, Torkildsen O, Wergeland S, et al
    WT1 and interferon-beta-vitamin D association in MS: a longitudinal study.
    Acta Neurol Scand. 2016;133:309-12.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: